Simultaneous Integrated Boost Irradiation After Breast-Conserving Surgery: Physician-Rated Toxicity and Cosmetic Outcome at 30 Months’ Follow-Up

Bantema-Joppe, Enja J.; Schilstra, Cornelis; Bock, Geertruida H. de; Dolsma, W.V.; Busz, D.; Langendijk, Johannes A.; Maduro, John H.

doi:10.1016/j.ijrobp.2012.01.050

Cited by 60 publications

(44 citation statements)

References 20 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36,39,43,50,53,55,56 However, the results from these studies were consistent with the results from studies amenable to pooling. We used the IASP criteria for the definition of persistent pain in this review; however, 14 of the included studies did not report whether their assessment of persistent postsurgical pain excluded other causes of pain; 26,[33][34][35][36]43,45,47,48,50,51,54,56,58 as such, they may have overestimated the prevalence of persistent pain.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Wang

Guyatt

Kennedy

et al. 2016

CMAJ

242

239

View full text Add to dashboard Cite

D espite a 10-year survival rate of 83%, 1,2 between 25% and 60% of surviving patients who have undergone surgery for breast cancer experience persistent postsurgical pain, [3][4][5][6][7][8][9] which is associated with reduced quality of life and functional impairment. [10][11][12][13] Systematic reviews summarizing proposed risk factors for persistent pain after breast cancer surgery -including demographic, intraoperative and postoperative factors -have had several limitations, including outdated searches, inadequate attention to risk-of-bias assessment, lack of statistical pooling of measures of association and failure to evaluate the quality of evidence.5,10-14 We conducted a systematic review and meta-analysis of observational studies to identify risk factors for persistent pain after breast cancer surgery, addressing the limitations of previous reviews. MethodsWe completed our systematic review in accordance with the MOOSE statement 15 and registered our protocol with PROSPERO (registration CRD42014013338). Background: Persistent pain after breast cancer surgery affects up to 60% of patients. Early identification of those at higher risk could help inform optimal management. We conducted a systematic review and meta-analysis of observational studies to explore factors associated with persistent pain among women who have undergone surgery for breast cancer. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

show abstract

Section: Strengths and Limitationsmentioning

confidence: 99%

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Wang

Guyatt

Kennedy

et al. 2016

CMAJ

242

239

View full text Add to dashboard Cite

show abstract

“…5-year local control was 98.9% [36]. Regarding toxicity and cosmetic outcome, after a median follow-up time of 30 months (range 6-54 months), 8.5% of patients had ≥ G2 fibrosis in the boost area, chest wall pain was detected in 6.7%, and teleangiectasia was detected in 3.7% (≥ G2) [37]. Half of the patients developed all-grade fibrosis outside the tumor bed.…”

Section: Boosting the Tumor Bedmentioning

confidence: 99%

Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence

et al. 2014

View full text Add to dashboard Cite

Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.

show abstract

“…skin, subcutaneous tissue, ribs [9]). This topic was addressed by Bantema-Joppe et al [1] who recently reported their experience with the SIB technique in a publication that prompted the present editorial. Between 2005 and 2010, 940 patients were treated by standardfractionated WBI (28 fractions of 1.8 Gy) and SIB regimen of 2.3-2.4 Gy.…”

Section: Statement Of the German And The Austrian Societies Of Radioomentioning

confidence: 91%

Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

et al. 2013

View full text Add to dashboard Cite

Simultaneous Integrated Boost Irradiation After Breast-Conserving Surgery: Physician-Rated Toxicity and Cosmetic Outcome at 30 Months’ Follow-Up

Cited by 60 publications

References 20 publications

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence

Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

Contact Info

Product

Resources

About